tradingkey.logo
tradingkey.logo
検索

Emergent BioSolutions Inc

EBS
ウォッチリストに追加
8.280USD
+0.010+0.12%
終値 07/02, 13:00ET15分遅れの株価
428.90M時価総額
損失額直近12ヶ月PER

詳細情報 Emergent BioSolutions Inc 企業名

Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.

Emergent BioSolutions Incの企業情報

企業コードEBS
会社名Emergent BioSolutions Inc
上場日Nov 15, 2006
最高経営責任者「CEO」Papa (Joseph C)
従業員数900
証券種類Ordinary Share
決算期末Nov 15
本社所在地300 Professional Dr
都市GAITHERSBURG
証券取引所NASDAQ OMX NASDAQ Basic NYSE
United States of America
郵便番号20879
電話番号12406313200
ウェブサイトhttps://emergentbiosolutions.com/
企業コードEBS
上場日Nov 15, 2006
最高経営責任者「CEO」Papa (Joseph C)

Emergent BioSolutions Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.82K
+61.58%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
267.95K
-1.48%
Ms. Jessica Perl
Ms. Jessica Perl
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
165.29K
+63.09%
Ms. Coleen Glessner
Ms. Coleen Glessner
Executive Vice President - Quality and Ethics and Compliance
Executive Vice President - Quality and Ethics and Compliance
153.92K
-1.31%
Mr. William Hartzel
Mr. William Hartzel
Senior Vice President - Manufacturing and Bioservices
Senior Vice President - Manufacturing and Bioservices
145.03K
-1.20%
Dr. Simon C Lowry, M.D.
Dr. Simon C Lowry, M.D.
Chief Medical Officer, Head of Research and Development
Chief Medical Officer, Head of Research and Development
116.59K
+85.86%
Dr. Zsolt Harsanyi, Ph.D.
Dr. Zsolt Harsanyi, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
114.67K
+22.10%
Mr. Ronald B. Richard
Mr. Ronald B. Richard
Independent Director
Independent Director
89.36K
+28.36%
Mr. Marvin L. White
Mr. Marvin L. White
Independent Director
Independent Director
79.44K
+31.90%
Mr. Keith A. Katkin, CPA
Mr. Keith A. Katkin, CPA
Independent Director
Independent Director
59.03K
+16.71%
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.82K
+61.58%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
267.95K
-1.48%
Ms. Jessica Perl
Ms. Jessica Perl
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
165.29K
+63.09%
Ms. Coleen Glessner
Ms. Coleen Glessner
Executive Vice President - Quality and Ethics and Compliance
Executive Vice President - Quality and Ethics and Compliance
153.92K
-1.31%
Mr. William Hartzel
Mr. William Hartzel
Senior Vice President - Manufacturing and Bioservices
Senior Vice President - Manufacturing and Bioservices
145.03K
-1.20%
Dr. Simon C Lowry, M.D.
Dr. Simon C Lowry, M.D.
Chief Medical Officer, Head of Research and Development
Chief Medical Officer, Head of Research and Development
116.59K
+85.86%

よくある質問

Emergent BioSolutions Incの上位5名の株主は誰ですか?

Emergent BioSolutions Incの上位5名の株主は以下のとおりです。Mr. Joseph C. (Joe) Papa

Emergent BioSolutions Inc(EBS)の株式を保有している機関の数はいくつですか?

2026Q1時点で、Emergent BioSolutions Incの株式を保有している機関は412社あり、保有株式の総市場価値は約42.30Mで、全体の81.98%を占めています。2025Q4と比較して、機関の持ち株は-3370363.00増加しています。

Emergent BioSolutions Incの最大の収益源は何ですか?

2026Q1において、Commercial Product sales部門がEmergent BioSolutions Incにとって最大の収益を生み出しており、その金額は223.30Mで、全収益の30.06%を占めています。